Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2022-01-28 Proxy Solicitation & In…
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes references to proxy materials such as the Notice and Proxy Statement and Form 10-K report, and instructions for voting proxies. The document is titled 'Definitive Additional Materials' related to a proxy statement, which aligns with materials sent to shareholders to provide information and request votes for meetings. The document length is relatively short (3041 characters) and it does not contain the full proxy statement itself but additional materials related to it. Therefore, the document fits best under the category 'Proxy Solicitation & Information Statement' (PSI).
2022-01-28 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, specifically a Definitive Additional Materials proxy statement related to the 2022 Annual Meeting of Stockholders of Enochian Biosciences Inc. It includes details about the virtual meeting, voting instructions, and references the proxy statement and annual report availability. The content is focused on soliciting shareholder votes and providing information for the annual meeting, which aligns with Proxy Solicitation & Information Statement filings. It is not the annual report itself, nor an earnings release or other financial report. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2022-01-28 English
DEF 14A
Proxy Solicitation & Information Statement
2022-01-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an "Other Events" section where a shareholder letter providing updates on clinical progress and business development is attached as Exhibit 99.1. The document is only 3051 characters long, which is relatively short and primarily serves as an announcement of the shareholder letter rather than containing detailed financial data or comprehensive reports. There is no indication of full financial statements, audit results, or detailed management discussion. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 8-K filings announcing events or attachments.
2022-01-24 English
Director's Dealing 2022
Director's Dealing
2022-01-11 English
Director's Dealing 2022
Director's Dealing
2022-01-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.